Article Text

Download PDFPDF

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C
Free
  1. U Siebert1,
  2. G Sroczynski2,
  3. S Rossol3,
  4. J Wasem4,
  5. U Ravens-Sieberer5,
  6. B M Kurth6,
  7. M P Manns7,
  8. J G McHutchison8,
  9. J B Wong9,
  10. German Hepatitis C Model (GEHMO) Group,
  11. International Hepatitis Interventional Therapy (IHIT) Group
  1. 1Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA, and Institute of Medical Informatics, Biometry and Epidemiology, University of Munich, Germany
  2. 2Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
  3. 3Gastroenterological and Hepatological Outpatient Clinic for Internal Medicine, University Hospital of Mannheim, Germany
  4. 4Institute for Health Care Management, University of Greifswald, Greifswald, Germany
  5. 5Health Outcomes Research Group, Robert Koch-Institute, Berlin, Germany
  6. 6Department for Epidemiology and Health Reporting, Robert Koch-Institute, Berlin, Germany
  7. 7Department of Gastroenterology and Hepatology, Medical School of Hanover, Hanover, Germany
  8. 8Scripps Clinic, La Jolla, CUInvestigators and institutions participating in the International Hepatitis Interventional Therapy Group Investigators and institutions participating in the International Hepatitis Interventional Therapy Group Investigators and institutions participating in the International Hepatitis Interventional Therapy Group
  9. 9Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
  1. Correspondence to:
    Dr J B Wong, Tufts-New England Medical Center, 750 Washington St, Box 302, Boston, MA 02111, USA;
    jwong{at}lifespan.org

Abstract

Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive.

Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C.

Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate.

Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of 11 800 and 6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments.

Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.

  • cost effectiveness analysis
  • hepatitis C
  • interferon α-2b
  • peginterferon α-2b
  • ribavirin
  • decision making
  • QALY, quality adjusted life year
  • SVR, sustained virological response rate

Statistics from Altmetric.com

Footnotes

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.